Company record
Midas Pharmaceuticals, Inc. provides sourcing, supply and development of pharmaceutical intermediates, finished products and active ingredients for the drug‑manufacturing sector. The portfolio spans critical, advanced and hazardous intermediates, reactives, fine chemicals, drug substances, finished dosage forms (FDFs), generic compounds and consumer‑healthcare items. Specific chemicals offered include R‑3‑quinuclidinol, sodium borohydride, trifluoroacetic acid, 5‑amino‑4‑oxopentanoic acid hydrochloride, crotamiton, diethylpropion hydrochloride, doxapram hydrochloride, doxazosin mesylate, ketoprofen, pipamperone dihydrochloride, trospium chloride and warfarin sodium. Products are packaged in a variety of formats such as blister packs, syringes, vials, cartridges, glass and plastic bottles, drums, closures and other containers. In addition, Midas Pharmaceuticals delivers a full suite of complementary services that encompass biotech support, business development and licensing, contract packaging, custom synthesis and API manufacturing, finished‑product development and manufacturing, as well as intellectual‑property, quality‑management and regulatory‑affairs consulting
This directory record does not yet have a linked material-flow brief.